1529807-52-0

Basic information

• Product Name: [¹⁴C]-[(2,5-dichlorobenzoyl)amino]acetic acid
• Synonyms: [¹⁴C]-[(2,5-dichlorobenzoyl)amino]acetic acid
• CAS NO: 1529807-52-0
• Molecular Weight: 250.054
• Mol File: 1529807-52-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [¹⁴C]-[(2,5-dichlorobenzoyl)amino]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [¹⁴C]-[(2,5-dichlorobenzoyl)amino]acetic acid(1529807-52-0)
• EPA Substance Registry System: [¹⁴C]-[(2,5-dichlorobenzoyl)amino]acetic acid(1529807-52-0)

Safety Data

• Hazardous Substances Data: 1529807-52-0(Hazardous Substances Data)

Usage

General Description

[¹⁴C]-[(2,5-dichlorobenzoyl)amino]acetic acid is a radiolabeled compound used in scientific research to study the metabolism and pharmacokinetics of the parent compound, [(2,5-dichlorobenzoyl)amino]acetic acid. The radiolabeling with [¹⁴C] allows researchers to track the compound in biological systems and determine its distribution, metabolism, and excretion. This information is valuable for understanding the compound's potential as a drug or environmental contaminant. The chemical structure of [(2,5-dichlorobenzoyl)amino]acetic acid contains a benzoyl group and an aminoacetic acid moiety, both of which are important for its biological activity and interactions with enzymes and receptors. Overall, the radiolabeled compound provides a powerful tool for investigating the behavior of [(2,5-dichlorobenzoyl)amino]acetic acid in living systems.

Upstream product

• 1529807-51-9 [¹⁴C]-methyl-[(2,5-dichlorobenzoyl)amino]acetate 
• 1435-50-3 2-bromo-1,4-dichlorobenzene 

Downstream Products

• 1529807-54-2 [¹⁴C]-(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid 
• 1529807-55-3 [¹⁴C]-(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid 
• 1529807-53-1 [¹⁴C]-2,5-dichloro-N-[2-({(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioaxaborol-2-yl]butyl}amino)-2-oxoethyl]benzamide 

Relevant articles and documents

Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708

MLN9708 (ixazomib citrate) is an investigational, orally bioavailable proteasome inhibitor that is under development by Millennium in clinical studies in both hematologic and nonhematologic malignancies. The stable isotope-labeled MLN9708 was required for bio-analytical studies. [13C 9]-MLN9708 (11) was synthesized in seven steps from the uniformly labeled [13C6]-1,4-dichlorobenzene (3) and [1- 13C]-acetyl chloride. Because of the presence of two chlorine atoms and a boron atom, compound 6 was further reacted with [13C 2]-glycine to provide an internal standard that is well separated from the parent compound during mass spectrometric analysis. The radiolabeled version was prepared to support metabolite profiling and whole body autoradiography studies in experimental animals. [14C]-MLN9708 (19) was synthesized in six steps from commercially available [14C]-barium carbonate. The key intermediate, [carboxyl-14C]-2,5-dichlorobenzoic acid (14), was prepared by selective lithiation of 1-bromo-2,5-dichlorobenzene (12) followed by carbonation with [14C]-barium carbonate. In preparation for a one-time human absorption, distribution, metabolism and excretion (ADME) study, the stability of [14C]-MLN9708 and its precursors were also evaluated. Copyright